GlassScriptPhysician profile
Steven J Morgenstern
NPI 1417916651
$12,601.90
in general payments reported to CMS, 2019-2025
35 companies · $89.98 in 2025
The $89.98 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,382 · 2020: $2,114 · 2021: $2,775 · 2022: $2,565 · 2023: $2,129 · 2024: $547 · 2025: $89.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,765.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,088.24 | 2019-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $1,884.00 | 2019-2024 | |
| Pfizer INC. | $936.87 | 2019-2023 | |
| Lilly USA, LLC | $832.08 | 2020-2023 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $691.11 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Amgen INC. | $643.86 | 2019-2023 | Otezla |
| Amarin Pharma, INC. | $586.87 | 2019-2022 | |
| Allergan, INC. | $510.08 | 2019-2020 | |
| Glaxosmithkline, LLC. | $466.98 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $463.79 | 2022-2023 | |
| Novo Nordisk INC | $421.55 | 2019-2023 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $396.47 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $350.40 | 2019-2023 | |
| Dexcom, INC. | $327.26 | 2021-2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $310.99 | 2019-2023 | Trintellix |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $262.35 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $254.96 | 2019-2023 | Jardiance, Tradjenta |
| Abbott Laboratories | $248.69 | 2020-2023 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $125.88 | 2022 | |
| Valeritas, INC. | $113.53 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $99.36 | 2019-2023 | Austedo Xr, Austedo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $91.49 | 2020-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $87.17 | 2019-2022 | |
| Daiichi Sankyo INC. | $62.21 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $58.49 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $54.42 | 2019-2021 | |
| Zealand Pharma US, INC. | $45.74 | 2020-2021 | |
| Sanofi Pasteur INC. | $41.93 | 2023 | |
| Sunovion Pharmaceuticals INC. | $33.80 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $25.67 | 2019-2021 | |
| Currax Pharmaceuticals LLC | $25.43 | 2020 | |
| Insulet Corporation | $18.95 | 2021 | |
| Astellas Pharma US INC | $17.20 | 2019 | |
| Axsome Therapeutics, INC. | $13.24 | 2023 | Sunosi |
| Horizon Therapeutics Plc | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Morgenstern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.